Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.
Read the full article:
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE)
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv